Luo Yijun, Lei Wenqian, Wang Xiaoli
Department of Oncology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi 330000, P.R. China.
Department of Oncology, Hejiang County People's Hospital, Luzhou, Sichuan 646200, P.R. China.
Mol Clin Oncol. 2025 Aug 20;23(5):96. doi: 10.3892/mco.2025.2891. eCollection 2025 Nov.
Brain metastases (BMs) frequently occur in non-small cell lung cancer (NSCLC) and are associated with a poor prognosis. Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have shown notable potential in treating patients with NSCLC and BMs due to their enhanced ability to cross the blood-brain barrier. However, failure pattern analyses reveal that initial disease progression (PD) in most patients primarily occurs in the brain, with >50% of cranial PD occurring exclusively at the original metastatic sites. This highlights the potential clinical importance of craniocerebral radiotherapy. Nevertheless, current clinical research indicates that not all patients with BMs will benefit from combined craniocerebral radiotherapy. Therefore, a comprehensive evaluation of relevant clinical factors is essential before selecting the most suitable treatment approach for these patients.
脑转移瘤（BMs）在非小细胞肺癌（NSCLC）中频繁发生，且与预后不良相关。表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）因其穿越血脑屏障的能力增强，在治疗NSCLC和BMs患者方面显示出显著潜力。然而，失败模式分析表明，大多数患者的初始疾病进展（PD）主要发生在脑部，超过50%的颅内PD仅发生在原始转移部位。这凸显了颅脑放疗的潜在临床重要性。尽管如此，目前的临床研究表明，并非所有BMs患者都能从联合颅脑放疗中获益。因此，在为这些患者选择最合适的治疗方法之前，对相关临床因素进行全面评估至关重要。
